Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Ripretinib

INVICTUS

Deciphera Pharmaceuticals · Phase 3 · Completed · Enrollment 129

NCT03353753

ArmPopulationDoseEstimandComparatorEfficacy
Ripretinib 150 mgGIST after imatinib, sunitinib and regorafenib150 mgITTplacebomedian progression-free survival (BICR): 6.3 months, primary analysisprogression-free survival hazard ratio vs placebo: 0.15 HR, primary analysisobjective response rate (BICR): 9%, primary analysismedian overall survival: 15.1 months, not tested for significance
PlaceboGIST after imatinib, sunitinib and regorafenibplaceboITTn/rmedian progression-free survival (BICR): 1 months, primary analysismedian overall survival: 6.6 months, 66% switched to ripretinib